A kinetic solution for the paradoxical difference between F-Dopa and methionine

Letter to the Editor
  • 190 Downloads

References

  1. 1.
    Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017;44(7): 1155–64. doi:10.1007/s00259-017-3618-3.CrossRefPubMedGoogle Scholar
  2. 2.
    Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, et al. IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas. Eur J Nucl Med Mol Imaging. 2017;44(8):1–6. doi:10.1007/s00259-017-3668-6.Google Scholar
  3. 3.
    Verger A, Taieb D, Guedj E. Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas Eur J Nucl Med Mol Imaging. 2017;44(8):1408–10. doi:10.1007/s00259-017-3710-8.CrossRefPubMedGoogle Scholar
  4. 4.
    Lopci E. The simplest explanation is usually the correct one—Can Occam’s razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?. Eur J Nucl Med Mol Imaging. 2017;44(8). doi:10.1007/s00259-017-3708-2.
  5. 5.
    Comar D, Cartron J C, Maziere M, Marazano C. Labelling and metabolism of methionine-methyl-11C. Eur J Nucl Med. 1976;1(1):11–4. doi:10.1007/BF00253260.CrossRefPubMedGoogle Scholar
  6. 6.
    Garnett E, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983; 305(5930):137–8. doi:10.1038/305137a0.CrossRefPubMedGoogle Scholar
  7. 7.
    Heiss W, Wienhard K, Wagner R, Lanfermann H, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37(7):1180–2.PubMedGoogle Scholar
  8. 8.
    Becherer A, Karanikas G, Szabó M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F] fluorodopa and [11 C] methionine. Eur J Nucl Med Mol Imaging. 2003;30(11):1561–7. doi:10.1007/s00259-003-1259-1.CrossRefPubMedGoogle Scholar
  9. 9.
    Kumakura Y, Vernaleken I, Gründer G, Bartenstein P, Gjedde A, Cumming P. PET studies of net blood–brain clearance of FDOPA to human brain: Age-dependent decline of [18F] fluorodopamine storage capacity. J Cereb Blood Flow Metab. 2005;25(7):807–19. doi:10.1038/sj.jcbfm.9600079.CrossRefPubMedGoogle Scholar
  10. 10.
    Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007;48(10):1651–61. doi:10.2967/jnumed.106.039321.CrossRefPubMedGoogle Scholar
  11. 11.
    Kratochwil C, Combs S E, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro-oncology. 2013;16(3):434–40. doi:10.1093/neuonc/not199.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kameyama M, Umeda-Kameyama Y. Strategy based on kinetics of O-(2-[18F] fluoroethyl) -L-tyrosine ([18F] FET). Eur J Nucl Med Mol Imaging. 2016;43(12):2267–8. doi:10.1007/s00259-016-3470-x.CrossRefPubMedGoogle Scholar
  13. 13.
    Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res Rev. 1982;4(2):237–74. doi:10.1016/0165-0173(82)90018-2.CrossRefGoogle Scholar
  14. 14.
    Sokoloff L, Reivich M, Kennedy C, Des Rosiers M, Patlak C, Pettigrew K, et al. The [ 14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977; 28 (5): 897–916. doi:10.1111/j.1471-4159.1977.tb10649.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Albert N L, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging. 2016;43(5):1105–14. doi:10.1007/s00259-015-3276-2.CrossRefPubMedGoogle Scholar
  16. 16.
    Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28(6):696–703. doi:10.1007/s002590100537.CrossRefPubMedGoogle Scholar
  17. 17.
    Nakajima R, Abe K, Momose M, Fukushima K, Matsuo Y, Kimura K, et al. Optimization of scan initiation timing after 11C-methionine administration for the diagnosis of suspected recurrent brain tumors. Ann Nucl Med. 2017;31(2):190–7. doi:10.1007/s12149-016-1140-5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Diagnostic RadiologyTokyo Metropolitan Geriatric Hospital and Institute of GerontologyTokyoJapan
  2. 2.Division of Nuclear Medicine, Department of RadiologySchool of Medicine, Keio UniversityTokyoJapan
  3. 3.Department of Geriatric MedicineSchool of Medicine, The University of TokyoTokyoJapan

Personalised recommendations